Celldex won its phase 3 trials. The full safety data come next

The technology

Barzolvolimab is an antibody that binds KIT, a receptor that mast cells need to grow and survive. Mast cells release histamine and other signals that cause hives, itch and swelling. Block KIT and the mast cells die off, which Celldex tracks through falling serum tryptase.

In chronic spontaneous urticaria (CSU), that approach works well. Both phase 3 trials, with 1,939 patients, met the primary endpoint and every major secondary endpoint. About 42% to 46% of patients had no itch and no hives at week 12, against 9% to 13% on placebo, and the 150 mg arms reached 49.0% and 54.0% at week 24. Patients who failed omalizumab also responded.

The approach has limits. In prurigo nodularis, barzolvolimab depleted mast cells but did not reduce itch, and Celldex dropped the indication. A second molecule, CDX-622, targets soluble stem cell factor and TSLP, and in healthy volunteers it showed no pigment or blood count changes.

The odds

The scientific risk in CSU is largely gone. Celldex has two positive, placebo-controlled trials at two doses. Across the industry, 90.6% of drugs that reach an NDA or BLA filing are approved, per BIO, Informa and QLS data for 2011 to 2020. Celldex plans to file in 2027, while treatment in both trials continues to 52 weeks.

Other indications carry normal mid-stage risk. The atopic dermatitis phase 2 reads out in late 2026, and the PN result is a reminder that mast cell biology does not carry over automatically. A phase 3 in cold urticaria and symptomatic dermographism is enrolling.

The money

Celldex had $717.6 million at June 30 after raising $345.0 million gross in April. It guides to funding planned operations through 2028. The second-quarter net loss was $73.5 million, and costs are rising as the company plans a launch. There is no product revenue, and general and administrative costs are rising with commercial planning. Shares outstanding were 78.5 million at June 30, up from 66.6 million at March 31, so the raise diluted holders by about 18%.

The risks

Safety is the main open question. In phase 2 CSU testing, the most common side effects in more than 10% of treated patients included hair color changes, neutropenia and skin hypopigmentation, which Celldex says were reversible. The Sept. 22 release gave no adverse event rates, only that the drug was well tolerated through 24 weeks.

Competition is the second risk. Novartis's oral remibrutinib was approved for CSU in September 2025, and patients and payers may prefer a pill. Celldex also has to build a commercial team while its CFO of nine years retires by March 31, 2027.

Our read

The efficacy is the best case Celldex could have hoped for, and the cash covers a filing and the start of a launch. The company also has a pipeline beyond CSU, with cold urticaria in phase 3 and CDX-622 in early testing, which gives it more than one path if the first launch is slow. What matters now is the full safety picture: adverse event rates, neutrophil counts and pigment changes over 52 weeks. If those look manageable, barzolvolimab has a strong argument as the option for patients who want complete control. If they do not, a high complete response rate will be a harder case to make against a daily pill.